Helicobacter pylori infection
Conditions
Interventions
A:colloidal bismuth pectin+amoxicillin+clarithromycin+esomeprazole+live combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules (d1-d14)
B:live combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules (d1-d14), colloidal bismuth pectin+amoxicillin+clarithromycin+esomeprazole (d15-d28)
C:colloidal bismuth pectin+amoxicillin+clarithromycin+esomeprazole (d1-d14), live combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules (d15-d28)
D:colloidal bismuth pectin+amoxicillin+clarithromycin+esomeprazole (d1-d14)
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosis of helicobacter pylori infection, and haven't received the anti-helicobacter pylori treatment; (2) Have no history of allergy to penicillin, clarithromycin, bismuth agent; (3) Aged 18 to 65 years old, male or female, regardless of gender, nationality.
Exclusion criteria
Exclusion criteria: (1) Pregnant or breast-feeding women; (2) Have taken antibiotics or H2RA or PPI within 2 weeks before treatment; (3) Serious heart, kidney, lung, and liver disease; (4) Drug or alcohol abuse; (5) Can not insist using drugs and participated in other clinical research; (6) Allergic constitution, known or suspected allergy to drugs using in this study; (7) Non-compliant patient; (8) The clinical trial research personnel.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hp eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| epigastric distention;belching;epigastric pain;diarrhea;loss of appetite;nausea;vomiting;acid regurgitation;heartburn;rash;Oral malodor;bitter taste; | — |
Countries
China
Contacts
Public ContactZhao Ying
Department of Gastroenterology, West China Hospital, Sichuan University
Outcome results
None listed